Entrectinib

Drug Overview

Entrectinib is an oral, selective tyrosine kinase inhibitor (TKI) designed to target specific, actionable oncogenic fusions, primarily involving the Neurotrophic Tyrosine Receptor Kinase (NTRK), ROS1, and ALK genes. It is a key example of a Targeted Therapy and a Smart Drug, notably approved for use across different tumor types based on genetic testing.

• Generic Name: Entrectinib
• US Brand Names: Rozlytrek®
• Drug Class: Tyrosine Kinase Inhibitor (TKI), Receptor Tyrosine Kinase (RTK) Inhibitor
• Route of Administration: Oral Capsule
• FDA Approval Status: Approved for locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ROS1-positive, and for solid tumors that are NTRK gene fusion-positive.

What Is It and How Does It Work? (Mechanism of Action)

Entrectinib blocks the enzymatic activity of the NTRK, ROS1, and ALK fusion proteins. These proteins become constitutively active due to gene rearrangement and drive uncontrolled growth and survival signals in cancer cells.

• Molecular Targets (NTRK, ROS1, ALK Kinases): Entrectinib is an inhibitor of the three NTRK proteins (TRKA, TRKB, and TRKC), the ROS1 proto-oncogene, and the ALK (Anaplastic Lymphoma Kinase) receptor.
• Action (ATP Competitive Inhibition): Entrectinib binds to the active site of these kinases, preventing the binding of the energy molecule ATP. This blocks the kinase from initiating downstream signaling.
• Result (Signaling Blockade and Apoptosis): By shutting down the activity of these oncogenic fusion proteins, Entrectinib inhibits tumor cell proliferation, induces cell death, and shrinks tumors.
• Bone Affinity: Not applicable. Entrectinib is a systemic oral kinase inhibitor and does not possess selective affinity for bone mineral components.

FDA Approved Clinical Indications

Entrectinib holds approvals for specific genetic subsets of cancers, demonstrating the power of precision oncology.

Oncological Uses

1. NTRK Gene Fusion-Positive Solid Tumors: Indicated for adults and pediatric patients aged 12 years and older with solid tumors that have an NTRK gene fusion, are locally advanced or metastatic, and for which surgical resection is likely to result in severe morbidity. This is a tissue-agnostic (site-independent) approval.
2. ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Indicated for adults with locally advanced or metastatic ROS1-positive NSCLC.

Non-oncological Uses

1. There are currently no FDA-approved non-oncological indications for Entrectinib.
2. Its mechanism is tightly focused on reversing oncogenic fusion protein activity.

Dosage and Administration Protocols

Entrectinib is administered as a daily oral capsule. Consistent dosing and patient adherence are essential for maintaining therapeutic drug levels and preventing resistance.

• Dose Reduction: Required for managing treatment-emergent adverse events, including central nervous system (CNS) effects, liver enzyme elevation, or cardiac abnormalities. Doses are typically reduced to 400 mg, then 200 mg daily.
• Renal Insufficiency: No dose adjustment is generally required for patients with mild to severe renal impairment.
• Hepatic Insufficiency: Dose reduction (e.g., to 300 mg daily) is required for patients with moderate to severe hepatic impairment (Child-Pugh B or C) due to the drug’s metabolism.

Standard Dosing for Oncological Indications

Clinical Efficacy and Research Results

Entrectinib has demonstrated compelling clinical efficacy, defined by high objective response rates and notable durability, particularly in treating challenging brain metastases, across multiple tumor types. This data is primarily drawn from integrated analyses of the STARTRK-2, STARTRK-1, and ALKA-372-001 trials.

• NTRK Gene Fusion-Positive Tumors (Integrated Efficacy Analysis – 2020-2025 Context):
  • Objective Response Rate (ORR): Entrectinib demonstrated a high ORR of approximately 57 percent across a range of solid tumor types bearing NTRK fusions.
  • Duration of Response (DOR): The median duration of response was robust, lasting around 10.4 months.
• ROS1-Positive Non-Small Cell Lung Cancer (NSCLC):
  • Objective Response Rate (ORR): Achieved an ORR of approximately 78 percent in patients who had not received prior TKI therapy.
• Progression-Free Survival (PFS): The median Progression-Free Survival in TKI-naïve ROS1 NSCLC was approximately 19 months, indicating sustained control in this specific lung cancer subset.
• Significance: These outcomes establish Entrectinib as a standard first-line targeted therapy option for patients whose cancers harbor these rare but highly actionable fusions, offering a chemotherapy-sparing treatment path with high response rates in the brain

Safety Profile and Side Effects

Black Box Warning

The side effect profile includes CNS effects, vision problems, and a risk of congestive heart failure.

Common Side Effects (Greater than 10 percent)

• Neurologic: Dysgeusia (altered taste, often metallic), dizziness (very common), paresthesia (tingling/numbness).
• Systemic: Fatigue, weight gain.
• Gastrointestinal: Constipation, diarrhea.

Serious Adverse Events

1. Congestive Heart Failure (CHF): Risk of severe or fatal CHF, particularly in patients with pre-existing cardiac conditions.
2. Central Nervous System (CNS) Effects: Severe dizziness, cognitive impairment, or confusion requiring dose reduction or interruption.
3. Hepatotoxicity: Liver enzyme elevation, requiring close monitoring.

Connection to Stem Cell and Regenerative Medicine

Entrectinib contributes to regenerative medicine by preserving crucial organ function, especially in the brain, and offering an effective non-chemotherapy option.

• Neuro-Regenerative Support: By effectively controlling brain metastases (a common site for these fusions), Entrectinib preserves neurological function and prevents the need for destructive therapies like whole-brain radiation, thereby supporting the long-term regenerative potential of the central nervous system.
• Targeted DNA Protection: As a non-cytotoxic targeted agent, Entrectinib spares the patient’s rapidly dividing healthy cells, including bone marrow stem cells, contrasting sharply with chemotherapy and preserving the patient’s fitness for potential future stem cell transplantation (HSCT) or cellular therapies.

Patient Management and Practical Recommendations 

Pre-treatment Tests to Be Performed

Close monitoring is required for CNS toxicity and the potential for cardiovascular adverse events.

• Genetic Testing: Mandatory confirmation of the ROS1 or NTRK gene fusion using a validated assay.
• Cardiac Assessment: Baseline Echocardiogram or MUGA scan to determine Left Ventricular Ejection Fraction (LVEF).

Precautions During Treatment

• CNS Safety: Patients must be counseled on the high risk of dizziness and cognitive impairment, especially at the start of therapy.
• Vision Changes: Report any new or worsening visual symptoms immediately.

Do’s and Don’ts List

• DO report any new or worsening shortness of breath, fatigue, or ankle swelling, as these may indicate heart failure.
• DO use caution when driving or operating heavy machinery until you know how the medication affects your balance.
• DON’T consume grapefruit or grapefruit juice, as it is a strong CYP3A4 inhibitor.
• DON’T open, crush, or chew the capsules; swallow them whole.

Legal Disclaimer

The information provided herein regarding Entrectinib (Rozlytrek®) is intended for general informational purposes only and is directed towards an international audience of patients and healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or personalized treatment from a qualified oncologist. This drug involves risks including heart failure, CNS effects, and severe drug interactions. All individuals must consult their specific healthcare provider for information tailored to their medical condition and treatment regimen. Reliance on any information appearing on this guide is solely at your own risk.